Version 2.77

Panel Hierarchy

Details for each LOINC in Panel LHC-Forms

LOINC Name R/O/C Cardinality Example UCUM Units
55157-2 risperiDONE and 9-Hydroxyrisperidone panel - Serum or Plasma
Indent9393-0 risperiDONE [Mass/volume] in Serum or Plasma R ng/mL
Indent9383-1 9-Hydroxyrisperidone [Mass/volume] in Serum or Plasma R ng/mL
Indent9394-8 risperiDONE+9-Hydroxyrisperidone [Mass/volume] in Serum or Plasma O ng/mL

Fully-Specified Name

Component
Risperidone & 9-Hydroxyrisperidone panel
Property
-
Time
Pt
System
Ser/Plas
Scale
Qn
Method

Additional Names

Short Name
risperiDONE+9OH-Ris Pnl SerPl
Display Name
risperiDONE and 9-Hydroxyrisperidone panel
Consumer Name Alpha Get Info
risperiDONE and 9-Hydroxyrisperidone panel, Blood

Basic Attributes

Class
PANEL.DRUG/TOX
Type
Laboratory
First Released
Version 2.27
Last Updated
Version 2.73
Order vs. Observation
Order
Common Test Rank Get Info
11351
Panel Type
Panel

Language Variants Get Info

Tag Language Translation
es-ES Spanish (Spain) Panel de Risperidona y 9-Hidroxirisperidona:Propiedades mixtas (sólo paneles):Punto temporal:Suero o Plasma:Qn:
Synonyms: Cuantitativo
es-MX Spanish (Mexico) panel de risperiDONE y 9-Hydroxyrisperidone:-:Punto temporal:Suero o Plasma:Cuantitativo:
et-EE Estonian (Estonia) Risperidooni ja 9-hüdroksürisperidooni paneel:-:Pt:S/P:Qn:
Synonyms: Juhuslik Kvantitatiivne Plasma Seerum Seerum või plasma
fr-CA French (Canada) Rispéridone & 9-hydroxyrispéridone panel:-:Temps ponctuel:Sérum/Plasma:Quantitatif:
fr-FR French (France) Rispéridone et 9-hydroxyrispéridone panel:-:Ponctuel:Sérum/Plasma:Numérique:
it-IT Italian (Italy) Risperidone & 9-Idrossirisperidone, panel:-:Pt:Siero/Plasma:Qn:
Synonyms: Livelli farmacologici e tossicologia Panel Risperidone & 9-Idrossirisperidone Plasma Punto nel tempo (episodio) Set di prescrizione per livelli farmacologici e to Siero Siero o Plasma
nl-NL Dutch (Netherlands) risperidon & 9-hydroxyrisperidon panel:-:moment:serum of plasma:kwantitatief:
pt-BR Portuguese (Brazil) Risperidona & 9-Hidroxirisperidona painel:#N/A:Pt:Sor/Plas:Qn:
Synonyms: ; Risperidone+9OH-Ris Pnl; Risperidone+9OH-Ris; Risperidal; 9OH-Risperidone; Risperidone metAcolite; Point in time; Random; SerPl; SerPlas; SerP; Serum; SR; Plasma; Pl; Plsm; Quantitative; QNT; Quant; Quan; Drugs; Pan; Panl; PANEL.DRUG & TOXICOLOGY; PANEL.DRUG & TOXICOLOGY; DRUG/TOXICOLOGY
ru-RU Russian (Russian Federation) Рисперидон & 9-Гидроксирисперидон панель:-:ТчкВрм:Сыв/Плаз:Колич:
Synonyms: Количественный Плазма Сыворотка Сыворотка или Плазма Точка во времени;Момент
tr-TR Turkish (Turkey) Risperidon ve 9-Hidroksirisperidon paneli:-:Zmlı:Ser/Plaz:Kant:
zh-CN Chinese (China) 利培酮与9-羟基利培酮组套:-:时间点:血清/血浆:定量型:
Synonyms: 利培酮与9-羟基利培酮组套（组合、医嘱组、套餐、套餐医嘱、医嘱套餐、组合申请、组合项目）;维思通;瑞斯哌东;瑞司哌酮;利培酮与9-羟基利培酮（9-羟利培酮、帕潘立酮）医嘱组;利培酮代谢物;利培酮代谢产物;9-羟利培酮;帕潘立酮 利培酮代谢物;利培酮代谢产物;9-羟利培酮;帕潘立酮;6,7,8,9-四氢-3-(2-(4-(6-氟-1,2-苯并异恶唑-3-基)-1-哌啶基)乙基)-9-羟基-2-甲基-4H-吡啶并[2,1-a]嘧啶-4-酮;Paliperidone;INVEGA;INVEGA Sustenna;9-Hydroxyrisperidone;6,7,8,9-Tetrahydro-3-(2-(4-(6-fluro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-9-hydroxy-2- 医嘱套餐 医嘱套餐类 医嘱套餐组 医嘱组 医嘱组.药物/毒理学试验;组套（组合、医嘱组、套餐、套餐医嘱、医嘱套餐、组合申请、组合项目）.药物/毒理学;医嘱组.药物与毒理学;医嘱组.药物与毒理学试验;医嘱组类.药物/毒理学;医嘱组类.药物/毒理学试验;医嘱组类.药物与毒理学;医嘱组类.药物与毒理学试验;实验室医嘱组类.药物/毒理学;实验室医嘱组类.药物/毒理学试验;实验室医嘱组类.药物与毒理学;实验室医嘱组类.药物与毒理学试验;药物与毒理学医嘱组;药物与毒理学医嘱组类 医嘱组合 医嘱组合类 医嘱组套 医嘱组套类 医嘱组类 可用数量表示的;定量性;数值型;数量型;连续数值型标尺 套餐 套餐医嘱 套餐医嘱组 套餐医嘱组类 实验室医嘱套餐 实验室医嘱套餐类 实验室医嘱组 实验室医嘱组合类 实验室医嘱组套 实验室医嘱组套类 实验室套餐医嘱组 实验室套餐医嘱组类 实验室检验项目医嘱组合类 实验室检验项目组合类 时刻;随机;随意;瞬间 检验医嘱组合类 检验项目医嘱组合类 检验项目组合类 毒品 毒品类 组 组合 组合医嘱 组合类 组套 维思通;瑞斯哌东;瑞司哌酮;3-[2-[4-(6-氟-1,2-苯并异噁唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-2-甲基-4H-吡啶并[1,2-α]嘧啶-4-酮;risperidone;3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-α]pyrimidin-4-one;Risperidone intermediates;Risperi 维思通;瑞斯哌东;瑞司哌酮;利培酮与9-羟利培酮医嘱组;利培酮代谢物;利培酮代谢产物;9-羟利培酮;帕潘立酮 药品类 药物 药物/毒理学;药物/毒理学试验;药物毒理学试验;药物毒理学试验类 药物类 血清或血浆

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=55157-2
Questionnaire definition
https://fhir.loinc.org/Questionnaire/?url=http://loinc.org/q/55157-2